Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nippon Shinyaku Co., Ltd. ( (JP:4516) ) just unveiled an announcement.
Nippon Shinyaku reported consolidated revenue of ¥170.8 billion for the year ended March 31, 2026, up 6.6%, while operating profit was flat and profit attributable to owners of the parent fell 8.7%, reflecting pressure on margins despite top-line growth. Total assets and equity expanded significantly, equity attributable to owners of the parent rose to ¥291.6 billion, and the company maintained a high equity ratio above 80%, indicating a solid balance sheet even as return on equity declined.
The company kept its annual dividend unchanged at ¥124 per share, lifting the payout ratio to 28.1%, and plans to maintain the same dividend level in the year to March 2027, signaling continued shareholder returns. For the next fiscal year, Nippon Shinyaku forecasts revenue growth to ¥200 billion and a recovery in profit, with basic earnings per share projected at ¥449.55, suggesting confidence in improving profitability despite short-term earnings softness.
The most recent analyst rating on (JP:4516) stock is a Hold with a Yen5200.00 price target. To see the full list of analyst forecasts on Nippon Shinyaku Co., Ltd. stock, see the JP:4516 Stock Forecast page.
More about Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange. It develops, manufactures, and sells prescription drugs and related healthcare products, focusing on specialty areas where it can maintain strong profitability and capital efficiency in the domestic and global markets.
Average Trading Volume: 288,654
Technical Sentiment Signal: Hold
Current Market Cap: Yen277B
For an in-depth examination of 4516 stock, go to TipRanks’ Overview page.